Chronic myeloid leukemia, pediatric

Section editor transclusions This page contains studies that were specific to pediatric populations. For the more general CML page, follow this link.

6 regimens on this page 7 variants on this page

AAML0123

References

1. COG AAML0123: Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Copoley LD, Heerema NA, Oehler V, Wood C, French ME, Arceci RJ, SMith FO, Bernstein ML. Higher Dose Imatinib for Children with De NoVo Chronic Phase Chronic Myelogenous Leukemia: A Report from the Children's Oncology Group. Pediatr Blood Cancer 2011 Jul 15;57(1):56-62. link to original article contains verified protocol NCT00030394

"How I Treat"

• 2019: Hijiya & Suttorp How I treat chronic myeloid leukemia in children and adolescents

Chronic phase, first-line therapy

Imatinib monotherapy

back to top

Regimen

Study	Years of enrollment	Evidence
Champagne et al. 2011 (COG AAML0123)	2002-2004	Phase II (RT)

Targeted therapy

• Imatinib (Gleevec) 340 mg/m² PO once per day

28-day cycles

References

1. COG AAML0123: Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Cooley LD, Heerema NA, Oehler V, Wood C, French ME, Arceci RJ, Smith FO, Bernstein ML. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Jul 15;57(1):56-62. Epub 2011 Apr 4. link to original article link to PMC article contains protocol PubMed NCT00030394

Nilotinib monotherapy

back to top

Regimen

Study	Years of enrollment	Evidence
Hijaya et al. 2019 (DIALOG)	2013-2015	Phase II (RT)

Targeted therapy

• Nilotinib (Tasigna) 230 mg/m² PO twice per day

Continued indefinitely

References

1. DIALOG: Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Aimone P, Allepuz A, Quenet S, Hourcade-Potelleret F, Hertle S, Sosothikul D. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 2019 Dec 5;134(23):2036-2045. link to original article contains verified protocol link to PMC article PubMed NCT01844765

Chronic phase, relapsed or refractory

Dasatinib monotherapy

back to top

Regimen

Study	Years of enrollment	Evidence
Gore et al. 2018 (CA180-226)	2009-2014	Phase II (RT)

Targeted therapy

• Dasatinib (Sprycel) 60 mg/m² PO once per day

Continued indefinitely

References

1. CA180-226: Gore L, Kearns PR, de Martino Lee ML, De Souza CA, Bertrand Y, Hijiya N, Stork LC, Chung NG, Cardos RC, Saikia T, Fagioli F, Seo JJ, Landman-Parker J, Lancaster D, Place AE, Rabin KR, Sacchi M, Swanink R, Zwaan CM. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. J Clin Oncol. 2018 May 1;36(13):1330-1338. Epub 2018 Mar 2. link to original article link to PMC article contains verified protocol PubMed NCT00777036

Nilotinib monotherapy

back to top

Regimen

Study	Years of enrollment	Evidence
(CAMN107A2120)	2011-NR	Phase 1, <20 pts (RT)

Note: there is no obvious publication of this trial.

Targeted therapy

• Nilotinib (Tasigna)

References

1. CAMN107A2120: NCT01077544